Compare NC & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NC | BNTC |
|---|---|---|
| Founded | 1913 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 379.8M | 454.2M |
| IPO Year | 2006 | 2020 |
| Metric | NC | BNTC |
|---|---|---|
| Price | $47.33 | $13.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $27.67 |
| AVG Volume (30 Days) | 11.9K | ★ 147.4K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | ★ 2.07% | N/A |
| EPS Growth | N/A | ★ 80.94 |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $104,778,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.60 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.43 | $9.85 |
| 52 Week High | $59.42 | $16.76 |
| Indicator | NC | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 42.58 | 59.30 |
| Support Level | $47.53 | $11.40 |
| Resistance Level | $51.09 | $14.35 |
| Average True Range (ATR) | 1.52 | 1.02 |
| MACD | -0.35 | 0.07 |
| Stochastic Oscillator | 31.80 | 61.21 |
NACCO Industries Inc is a holding company that operates in the mining and natural resource industries. It has three operating segments: Utility Coal Mining, Contract Mining, and Minerals and Royalties. The Utility Coal Mining segment, operated by North American Coal, manages surface coal mines that are exclusive, long-term fuel providers for power generation companies. The Contract Mining segment, operated by North American Mining, is a provider of a broad range of specialized, long-term contract mining services. The Minerals and Royalties segment, which includes the Catapult Mineral Partners (Catapult) business, acquires and promotes the development of mineral and royalty interests and other related investments.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.